Novo Nordisk A/S (NYSE:NVO) Shares Sold by JNBA Financial Advisors

JNBA Financial Advisors lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 47.8% during the third quarter, Holdings Channel.com reports. The institutional investor owned 2,187 shares of the company’s stock after selling 2,000 shares during the period. JNBA Financial Advisors’ holdings in Novo Nordisk A/S were worth $260,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. 1620 Investment Advisors Inc. purchased a new stake in Novo Nordisk A/S during the 2nd quarter worth about $25,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Orion Capital Management LLC acquired a new position in shares of Novo Nordisk A/S in the first quarter valued at approximately $26,000. Gilliland Jeter Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after buying an additional 120 shares during the period. Finally, Halpern Financial Inc. boosted its position in Novo Nordisk A/S by 113.0% during the second quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 4.3 %

NYSE NVO opened at $105.35 on Thursday. The firm has a market capitalization of $472.76 billion, a price-to-earnings ratio of 36.08, a PEG ratio of 1.43 and a beta of 0.42. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company’s 50 day moving average price is $122.65 and its 200 day moving average price is $130.59.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.01 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.